Filing Details

Accession Number:
0001415889-22-008896
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-19 16:06:50
Reporting Period:
2022-08-17
Accepted Time:
2022-08-19 16:06:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
744218 Celldex Therapeutics Inc. CLDX In Vitro & In Vivo Diagnostic Substances (2835) 133191702
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1709113 Sarah Cavanaugh C/O Celldex Therapeutics, Inc.
53 Frontage Road, Suite 220
Hampton NJ 08827
Svp Of Corp Affairs & Admin. No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-17 31,312 $2.78 32,596 No 4 M Direct
Common Stock Disposition 2022-08-17 31,312 $36.73 1,284 No 4 S Direct
Common Stock Acquisiton 2022-08-18 1,355 $9.02 2,639 No 4 M Direct
Common Stock Disposition 2022-08-18 1,355 $36.38 1,284 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Incentive Stock Option Disposition 2022-08-17 31,312 $0.00 31,312 $2.78
Common Stock Incentive Stock Option Disposition 2022-08-18 1,355 $0.00 1,355 $9.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,750 2029-06-19 No 4 M Direct
10,103 2028-06-13 No 4 M Direct
Footnotes
  1. Includes 876 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.54 to $37.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.09 to $36.65 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  4. 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
  5. As of June 13, 2022, the option is fully vested.